Research To Practice | Oncology Videos Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Sep 12, 2025
In this engaging conversation, Dr. Jacob Sands, a medical oncologist at Dana-Farber Cancer Institute, dives deep into the exciting world of TROP2-directed antibody-drug conjugates for non-small cell lung cancer. He discusses how to manage adverse events like stomatitis and interstitial lung disease associated with datopotamab deruxtecan. Dr. Sands also highlights the drug's impressive intracranial efficacy and explores the promising role of combining ADCs with immunotherapy, revealing potential breakthroughs in treatment strategies.
AI Snips
Chapters
Transcript
Episode notes
Manage Stomatitis Proactively
- Use steroid mouth rinses and ice chips to reduce stomatitis symptoms during datopotamab deruxtecan infusion.
- Consider dose reduction rather than stopping the drug if stomatitis is not tolerable, since lower doses retain efficacy.
Address Ocular Surface Toxicity Early
- Refer patients to ophthalmology before or promptly after starting Dato-DXd and start lubricating eye drops for dry-eye symptoms.
- Escalate to urgent ophthalmology if vision changes or a 'beefy red eye' develop.
Investigate Suspected ILD Thoroughly
- Maintain a high index of suspicion for interstitial lung disease (ILD) on Dato-DXd and perform a multidisciplinary workup when suspected.
- Do not assume radiographic changes are ILD without evaluating other causes, especially in smokers and lung cancer patients.